Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?

MK-1084 is a small molecule commercialized by Merck, with a leading Phase I program in Metastatic Colorectal Cancer.

UK to ban xylazine and 21 other substances to combat drug abuse

The powerful sedative xylazine has been detected in cannabis vapes. Credit: PavelKant/Shutterstock. The UK government has taken a significant step towards banning xylazine, commonly referred

September 5, 2024

Single-cell study identifies pro-metastatic cell subpopulations

Neuroblastoma (NB), the most prevalent extracranial solid tumor in children, poses a significant therapeutic challenge due to its metastasis and high heterogeneity. A recent study

November 4, 2024

FDA approves Vertex and CRISPR’s Casgevy as first CRISPR-edited therapy for beta-thalassemia

The FDA has approved Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy to treat beta-thalassemia, Vertex said Tuesday, making it the first-ever CRISPR-edited therapy for the rare

January 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.